SCHEMBL15902172

SCHEMBL15902172

CCOC(=O)COc1ccc2cc[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.55
PDE3A Q14432 2/20 0.55
P2RY12 Q9H244 2/20 0.55
MAOA P21397 1/20 0.54
GAA P10253 4/20 0.51
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 3/20 0.51
HPGD P15428 4/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 2/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
POLB P06746 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TP53 P04637 1/20 0.50
GLA P06280 1/20 0.50
CASP1 P29466 1/20 0.46
MCL1 Q07820 1/20 0.46
PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665845 0.89 PDE3B (0.55) PDE3BPDE3AP2RY12MAOAGAA
SCHEMBL6486614 0.86 MEN1 (0.57) MAOAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL16179786 0.82 MAOA (0.56) PDE3BPDE3AP2RY12MAOAGAA
SCHEMBL827340 0.80 MEN1 (0.65) MAOAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL6626983 0.79 MEN1 (0.62) MAOAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL27370553 0.78 PTPN7 (0.63) PDE3BPDE3AP2RY12GAAKDM4E
SCHEMBL10174322 0.78 GAA (0.57) PDE3BPDE3AP2RY12GAAKDM4E
SCHEMBL29282185 0.77 TSHR (0.47) PDE3BPDE3AP2RY12GAAALDH1A1
SCHEMBL6599615 0.77 HDAC1 (0.59) PDE3BPDE3AP2RY12MAOAPPARD
SCHEMBL6626981 0.77 MEN1 (0.61) MAOAKDM4EHSD17B10HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 CN disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
EP-2760831-B1 VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2019-08-07 EP disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 PDE3B 1974/4885PDE3A 2320/4885P2RY12 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.